Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,068 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
An G, Zhou D, Cheng S, Zhou K, Li J, Zhou J, Xie L, Jin J, Zhong L, Yan L, Guo H, Du C, Zhong J, Yu Y, Wu B, Qiu L. An G, et al. Among authors: jin j. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501. doi: 10.1158/1078-0432.CCR-21-0539. Epub 2021 Jul 12. Clin Cancer Res. 2021. PMID: 34253577 Free PMC article. Clinical Trial.
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
Yan X, Zhou Y, Huang S, Li X, Yu M, Huang J, Wang J, Ma Z, Jin J, Pan J, Li C, Li F, Jin J. Yan X, et al. Among authors: jin j. J Cancer Res Clin Oncol. 2018 Apr;144(4):697-706. doi: 10.1007/s00432-017-2570-8. Epub 2018 Feb 1. J Cancer Res Clin Oncol. 2018. PMID: 29392403
CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study.
Qian JJ, Hu X, Wang Y, Zhang Y, Du J, Yang M, Tong H, Qian WB, Wei J, Yu W, Lou YJ, Mao L, Tao Meng H, You LS, Wang L, Li X, Huang X, Cao LH, Zhao JZ, Yan Yan X, Chen YB, Chen Y, Zhang SJ, Jin J, Hu J, Zhu HH. Qian JJ, et al. Among authors: jin j. Cancer Med. 2020 Aug;9(15):5327-5334. doi: 10.1002/cam4.3079. Epub 2020 Jun 3. Cancer Med. 2020. PMID: 32492289 Free PMC article.
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj-Teague M, Zinzani PL, Coleman M, Thieblemont C, Browett P, Ke X, Sun M, Marcus R, Portell CA, Ardeshna K, Bijou F, Walker P, Hawkes EA, Mapp S, Ho SJ, Talaulikar D, Zhou KS, Co M, Li X, Zhou W, Cappellini M, Tankersley C, Huang J, Trotman J. Opat S, et al. Among authors: jin j. Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15. Clin Cancer Res. 2021. PMID: 34526366 Free PMC article.
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L, Zhang Y, Yao D, Chen D, Schecter JM, Yang F, Tian X, Sun H, Zhuang SH, Ren J, Fan X, Jin J, Niu T, Chen SJ. Mi JQ, et al. Among authors: jin j. J Clin Oncol. 2023 Feb 20;41(6):1275-1284. doi: 10.1200/JCO.22.00690. Epub 2022 Oct 21. J Clin Oncol. 2023. PMID: 36269898 Clinical Trial.
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Wang T, Sun X, Qiu L, Su H, Cao J, Li Z, Song Y, Zhang L, Li D, Wu H, Zhang W, Li J, Zhou K, Zhou H, Yang Y, Li Z, Cen H, Cai Z, Zhang Z, Fu W, Jin J, Li F, Wu W, Gu X, Zhu W, Liu L, Li Z, Yi S, Bao H, Xu Z, Qiu L. Wang T, et al. Among authors: jin j. Clin Cancer Res. 2023 Apr 14;29(8):1440-1449. doi: 10.1158/1078-0432.CCR-22-2939. Clin Cancer Res. 2023. PMID: 36735519 Free PMC article. Clinical Trial.
Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single-center pilot trial.
Zhou D, Huang X, Xie M, Zhu L, Huang X, Li X, Yang X, Li L, Zhu J, Zheng X, Sun J, Zhao S, Yu W, Xie W, Tong H, Jin J, Zhu H, Ye X. Zhou D, et al. Among authors: jin j. Am J Hematol. 2023 May;98(5):E106-E109. doi: 10.1002/ajh.26877. Epub 2023 Feb 22. Am J Hematol. 2023. PMID: 36789563 Free article. No abstract available.
Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xie M, Shi T, Jiang Q, Jia Y, Zhou D, Tong H, Jin J, Zhu HH. Xie M, et al. Among authors: jin j. Cancer. 2023 May 15;129(10):1523-1536. doi: 10.1002/cncr.34710. Epub 2023 Mar 7. Cancer. 2023. PMID: 36882308 Free article.
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study.
Huang H, Tao R, Hao S, Yang Y, Cen H, Zhou H, Guo Y, Zou L, Cao J, Huang Y, Jin J, Zhang L, Yang H, Xing X, Zhang H, Liu Y, Ding K, Qi Q, Zhu X, Zhu D, Wang S, Fang T, Dai H, Shi Q, Yang J. Huang H, et al. Among authors: jin j. J Clin Oncol. 2023 Jun 1;41(16):3032-3041. doi: 10.1200/JCO.22.02367. Epub 2023 Mar 30. J Clin Oncol. 2023. PMID: 36996373 Free PMC article. Clinical Trial.
13,068 results
You have reached the last available page of results. Please see the User Guide for more information.